Exactly, which is why trying to scare up concern among shareholders over Urano investigating a non-MANF approach is pointless. No one knows where his research will lead him or where it will end up, even Urano himself. There are so many indications where MANF is being tested, it's realistic to expect MANF might not turn out to be a viable treatment for many of them. We only need success in a few indications to have a great impact on our investment.